Lumateperone tosylate

Research use only, not for human use.

Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM).

Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM); also shows affinity for D1; orally bioavailable and exhibits good antipsychotic efficacy in vivo.Schizophrenia Phase 3 Clinical(In Vitro):Lumateperone (2-30 μM) tosylate has anti-tumor activity and can inhibit cell proliferation in a dose-dependent manner.(In Vivo):Lumateperone (i.p., 1-10 mg/kg) tosylate promotes NMDA and AMPA-induced currents in a dopamine D 1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices.

Lumateperone (2-30 μM) tosylate has anti-tumor activity and can inhibit cell proliferation in a dose-dependent manner. Cell Proliferation Assay Cell Line:RPMI-8226 cells Concentration:2-30 μM Incubation Time:Result: Inhibited cell growth with the IC50 value of 17.30 μM.

Lumateperone (i.p., 1-10 mg/kg) tosylate promotes NMDA and AMPA-induced currents in a dopamine D 1 receptor-dependent manner and increases the release of dopamine and glutamate in rat mPFC slices. Animal Model:Adult male Sprague-Dawley rats Dosage:1-10 mg/kg Administration:Intraperitoneal injection Result:Inhibited avoidance response at concentrations of 1, 3 and 10 mg/kg after 20 minutes.Promoted NMDA and AMPA-sensitive currents, also significantly increased dopamine and glutamate release at 10 mg/kg in mPFC cone cells of rat.

ITI-007

GPCR/G Protein

5-HT Receptor

5-HT Receptor

Neurological Disease

Schizophrenia

1187020-80-9

565.6987

C31H36FN3O4S

>98% (HPLC)

10 mM in DMSO

CC1=CC=C(C=C1)S(=O)(=O)O.CN1CCN2C3CCN(CC3C4=C2C1=CC=C4)CCCC(=O)C5=CC=C(C=C5)F

1-Butanone, 1-(4-fluorophenyl)-4-[(6bR,10aS)-2,3,6b,9,10,10a-hexahydro-3-methyl-1H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8(7H)-yl]-, 4-methylbenzenesulfonate (1:1)

(-20℃)

With Ice Pack

≥ 2 years